Renalytix Plc (LON:RENX – Get Free Report) traded up 10% during trading on Monday . The company traded as high as GBX 4.50 and last traded at GBX 4.11. Approximately 928,051 shares were traded during mid-day trading, an increase of 1% from the average session volume of 917,086 shares. The stock had previously closed at GBX 3.73.
Renalytix Stock Down 0.3%
The firm has a market capitalization of £18.74 million, a PE ratio of -1.07 and a beta of 1.81. The business’s fifty day moving average price is GBX 2.93 and its 200 day moving average price is GBX 2.67. The company has a quick ratio of 2.42, a current ratio of 1.57 and a debt-to-equity ratio of -483.33.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
See Also
- Five stocks we like better than Renalytix
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
